Capstone Therapeutics announces unregistered sale of shares under USD 20 million equity line
Capstone Holding Corp CAPS | 0.00 |
- Capstone Therapeutics entered an amended, restated equity line on June 11, 2026, allowing sales of up to USD 20 million of common stock.
- Shares may be sold in time-bracketed VWAP purchases at 97% of VWAP, with each draw capped at 1,000,000 shares or 25% of volume.
- The unregistered shares will be offered under Securities Act exemptions, including Section 4(a)(2) and Rule 506(b), to an accredited investor.
- About 4,975,197 shares were registered in June 2025; 1,543,400 shares have been issued through May 27, 2026.
- Joseph Gunnar to receive a 7% cash fee on each drawdown closing, with up to USD 15,000 in reimbursed expenses at the initial closing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020393), on June 12, 2026, and is solely responsible for the information contained therein.
